A. B. Dobrovol'skii

In vitro plasminogen activation by joint action of the tissue plasminogen activator and a urokinase—Ffbrinogen conjugate

A. Maksimenko, E. G. Tishchenko, A. B. Dobrovol'skii, 1998, Pharmaceutical Chemistry Journal.

Combined thrombolysis by joint action of the tissue plasminogen activator and A urokinase—fibrinogen conjugate upon sequential double bolus introduction in dogs with venous thrombosis model

A. Maksimenko, E. G. Tishchenko, A. B. Dobrovol'skii, 1998, Pharmaceutical Chemistry Journal.

Anticoagulant properties of the endothelium studied by the standard venous occlusion test

J. Bonnet, O. Averkov, A. B. Dobrovol'skii, 1992, Bulletin of Experimental Biology and Medicine.

Isolation and characterization of A protein C activator fromAgkistrodon contortrix contortrix venom

A. B. Dobrovol'skii, M. Smirnov, A. N. Storozhilova, 1989, Bulletin of Experimental Biology and Medicine.

[The effect of long-term Fraxiparin treatment on hemostasis in patients with primary pulmonary hypertension].

I. Chazova, E. Titaeva, A. B. Dobrovol'skii, 1997, Terapevticheskii arkhiv.

[Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].

E. Titaeva, N. Konovalova, A. B. Dobrovol'skii, 2011, Terapevticheskii arkhiv.

[Effects of low doses of activated protein C in experimental arterial thrombosis in rats].

A. B. Dobrovol'skii, V. L. Golubykh, M. Smirnov, 1990, Kardiologiia.

[Matrix metalloproteinases, C-reactive protein, and markers of thrombinemia in patients with stable angina and restenoses after percutaneous coronary interventions.].

E. Titaeva, I. V. Levitskii, V. Masenko, 2004, Kardiologiia.